Partnership to improve biodiversity research, accelerate conservation with actionable and accurate genomic data MENLO PARK, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality,

MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors

Omniome’s high accuracy short-read sequencing platform  expected to significantly expand PacBio’s market opportunity Acquisition expected to accelerate the adoption of SMRT Sequencing,  PacBio’s leading long-read sequencing platform PacBio also closes $300 million PIPE financing in support of

MENLO PARK, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Virtual Healthcare Conference on September 10, 2021, Fireside Chat at 12:40 pm

MENLO PARK, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conference: UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, Panel Discussion at 4:00 pm

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue reflects continued quarter-over-quarter growth Revenue for the second quarter of 2021 was

Technology Will Enable Continued End-to-End Automated Workflow Development MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted

Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc. Combining both highly accurate long and short read sequencing technologies expected to provide deeper clinical insights and lower the overall cost of analysis MENLO PARK, Calif.,

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets Brings together Omniome’s high accuracy short-read sequencing platform, with PacBio’s market leading, high accuracy long-read solutions Transaction supported by